TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Ocumension Therapeutics ( (HK:1477) ) is now available.
Ocumension Therapeutics announced that its biosimilar product OT-702, developed in collaboration with Shandong Boan Biotechnology, has received marketing approval from China’s National Medical Products Administration for treating neovascular age-related macular degeneration and diabetic macular edema. This approval positions Ocumension to potentially expand its market presence in China, leveraging its exclusive rights to promote and commercialize OT-702, which is similar to the globally approved EYLEA. The approval allows the company to apply for additional indications, potentially broadening its therapeutic offerings in the Chinese market.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in developing and commercializing ophthalmic therapies, particularly targeting eye diseases such as neovascular (wet) age-related macular degeneration and diabetic macular edema.
Average Trading Volume: 3,556,543
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.53B
See more data about 1477 stock on TipRanks’ Stock Analysis page.